1. Home
  2. STRO

as of 02-24-2026 9:30am EST

$18.50
+$0.10
+0.54%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Founded: 2003 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 85.0M IPO Year: N/A
Target Price: $18.88 AVG Volume (30 days): 117.6K
Analyst Decision: Hold Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.52 - $19.90 Next Earning Date: 01-01-0001
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 63.08% Revenue Growth (next year): -55.43%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: